High-cost GLP-1 weight-loss drugs are reshaping household budgets, prompting spending trade-offs and new financial planning needs, while access varies by income.
Thousands in England unable to access weight loss jabs via GP, figures reveal
NHS rollout of tirzepatide (Mounjaro) is underfunded, leaving many eligible patients unable to access prescriptions and creating a postcode lottery of access.